期刊文献+

HPV58型E1^E4蛋白的表达纯化和多克隆抗体的制备 被引量:2

Expression and Purification of HPV58 E1^E4 Fusion Protein and Preparation of Polyclonal Antibody Against HPV58 E1^E4
原文传递
导出
摘要 目的:构建pRSET-A\E1^E4原核表达载体,获得E1^E4蛋白的多克隆抗体。方法:在BL21(DE3)细胞中诱导E1^E4融合蛋白表达,收集包涵体经过镍柱纯化后免疫新西兰白兔,获得的抗血清经硫酸铵沉淀法纯化得到抗体。结果:经Western blotting检测表明制备的E1^E4蛋白多克隆抗体特异性较好。结论:成功获得了纯化的E1^E4蛋白抗体,有助于后续HPV58型E1^E4蛋白功能和B细胞抗原表位的研究。 Objective: To construct recombined plasmid pRSET-A/EI^E4, and to obtain polyclonal antibodies to El^E4 protein. Methods: The constructed recombined plasmid pRSET-AkEI^E4 was transfected into BL21 (DE3) strain to express the El^E4 protein. The inclusion body was collected and purified through Ni-NTA purification system. Polyclonal antibodies to the El^E4 protein were prepared by inoculating rabbits with purified recombinant protein and purified by ammol/Lonium sulfate. Results: The results of Western blotting showed that the prepared polyclonal antibodies had well specificity to EIAE4 protein of HPV58. Conclusion: The polyclonal antibod- ies to El^E4 protein of HPV58 were obtained successfully, which is helpful to research the function and B cell epitopes of this protein.
出处 《生殖与避孕》 CAS CSCD 2012年第7期433-437,共5页 Reproduction and Contraception
关键词 E1^E4蛋白 蛋白表达 包涵体纯化 抗体制备 El^E4 protein protein expression inclusion body purification preparation of polyclonal antibody
  • 相关文献

参考文献19

  • 1Munoz N. Human papillomavirus and cancer: the epidemio- logical evidence. J Clin Virol, 2000, 19(I-2): 1-5.
  • 2金玉姬,岳丽杰,陶林,邓芳梅,李德发,何文山,刘捷,项健,蔡虹,涂倩倩,洪敏.男性人乳头瘤病毒检测方法的建立及临床应用[J].中华男科学杂志,2008,14(2):106-109. 被引量:9
  • 3Walboomers JM, Jacobs MV, Manos MMOL/L, et al. Human papiUomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1):12-9.
  • 4Calleja-Macias IE, Villa LL, Prado JC, et al. Worldwide genomic diversity of the high-risk human papillomavirus types31, 35, 52, and 58, four close relatives of human papillomavirus typel6. J Virol, 2005, 79(21): 13630-40.
  • 5Chan PK, Lam CW, Cheung TH, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst, 2002, 94(16): 1249-301.
  • 6Lin QQ, Yu SZ, Qu w, et al. Human papillomavirus types 52 and 58. Int J Cancer, 1998, 75(3):484-5.
  • 7Wu Y, Chen Y, Li L, et al. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol, 2006, 35(3):264-72.
  • 8Huang S, Afonina I, Miller BA, et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chi- nese women. Int J Cancer, 1997, 70(4):408-11.
  • 9Lai HC, Sun CA, Yu MH, et al. Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. Int J Cancer, 1999, 84(6):553-7.
  • 10Lai CH, Huang HJ, Hsueh S, et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer, 2007, 120(9): 1999-2006.

二级参考文献8

  • 1de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses [ J], Virology, 2004, 324( 1 ) : 17-27.
  • 2Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses[ J], Lancet Oncol, 2005, 6(4):204.
  • 3Castellsague X, Bosch FX, Munoz N. The male role in cervical cancer[ J]. Salud Publica Mex, 2003, 45 ( Suppl 3 ) : S345-353.
  • 4Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: A systematic review of the literature[ J]. J Infect Dis, 2006, 194(8) :1044-1057.
  • 5Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen[J]. Cancer Epidemiol Biomarkers Prey, 2007, 16 (6) : 1107-1114.
  • 6Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses[ J]. J Clin Microbiol, 2000, 38(1) : 357-361.
  • 7Manos MM, Ting Y, Wright DK, et al. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses[ J]. Cancer Cells, 1989, 7( 1 ) : 209-214.
  • 8Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase [J]. Science, 1988, 239(4839) : 487-491.

共引文献8

同被引文献31

  • 1de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology, 2004, 324(1 ): 17-27.
  • 2Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine, 2012, 30(Suppl 5): F55-70.
  • 3Calteja-Macias IE, Villa LL, Prado JC, et al. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol, 2005, 79(21): 13630-40.
  • 4Wang SM, Li J, Qiao YL, et al. HPV prevalence and genotyping in the cervix of Chinese women. Front Med China, 2010, 4 (3):259-63.
  • 5Chan PKS, Cheung TH, Li WH, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer, 2012, 131 (3):692-705.
  • 6Ferlay J, Soerjomatamm 1, Ervik M, et al. GLOBOCAN 2012 vl.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Intemet].?Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr, accessed on 10/10/2015.
  • 7McBride AA. The Papillomavirus E2 proteins. Virology, 2013, 445(1-2):57-79.
  • 8Dillner L, Zellbi A, Avall-Lundqvist E, et al. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Cancer Detect Prey, 1995, 19 (5):381-93.
  • 9Lenner P, Dillner J, W iklund F, et al. Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carci- noma of the uterine cervix. Cancer Immunol Immunother, 1995, 40(3):201-5.
  • 10Sharma BK, Ray A, Murthy NS, et al. Prevalence of serum antibodies to synthetic peptides to HPV 16 epitopes among lndian women with cervical neoplasia. Eur J Cancer, 1996, 32A(5):872-6.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部